3-乙氧基苯甲醛 | 22924-15-8

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香醛(含缩醛,半缩醛)
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-乙氧基苯甲醛
• 中文别名: 间乙氧基苯甲醛
• 英文名称: 3-ethoxybenzaldehyde
• 英文别名: m-ethoxybenzaldehyde
• CAS: 22924-15-8
• 化学式: C₉H₁₀O₂
• mdl: MFCD00016606
• 分子量: 150.177
• InChiKey: QZMGMXBYJZVAJN-UHFFFAOYSA-N

物化性质

• 熔点：
  177 °C
• 沸点：
  243 °C(lit.)
• 密度：
  1.07 g/mL at 25 °C(lit.)
• 闪点：
  132-134°C/15mm
• LogP：
  2.180 (est)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解。应避免接触氧化物、碱以及空气中的还原剂。

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT, AIR SENSITIVE
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2912499000
• 危险性防范说明：
  P264,P280,P302+P352+P332+P313+P362+P364,P305+P351+P338+P337+P313
• 危险性描述：
  H315,H319
• 储存条件：
  请将贮藏器密封，并将其放入一个紧密封装的容器中。储存时应选择阴凉、干燥的地方。

SDS

Name:	3-Ethoxybenzaldehyde Material Safety Data Sheet
Synonym:	None Known
CAS:	22924-15-8

Section 1 - Chemical Product MSDS Name:3-Ethoxybenzaldehyde Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
22924-15-8	3-Ethoxybenzaldehyde	98	245-333-4

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled. Can produce delayed pulmonary edema.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 22924-15-8: Personal Protective Equipment Eyes: Wear chemical splash goggles.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 243 deg C @ 760 mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.07
Molecular Formula: C9H10O2
Molecular Weight: 150.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Strong bases, strong oxidizing agents, strong reducing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 22924-15-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Ethoxybenzaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 22924-15-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 22924-15-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 22924-15-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：淡黄色的油状液体。

反应信息

• 作为反应物：
  描述：

  3-乙氧基苯甲醛 在 (S)-联萘(3,5-二甲苯基)膦 、 bis(1,5-cyclooctadiene)iridium(I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以59%的产率得到苯乙醚
  参考文献：
  名称：

  阳离子铱催化剂通过醛C-H键裂解脱羰

  摘要：

  我们报告了通过阳离子铱/双膦催化剂催化的醛 C-H 键裂解使醛脱羰。该反应在相对温和的条件下进行，以中等至高产率得到相应的烃产物。此外，这种阳离子铱催化剂体系可用于酮的不对称加氢酰化。

  DOI：

  10.1055/s-0037-1611802
• 作为产物：
  描述：

  碘乙烷 、 间羟基苯甲醛 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以66%的产率得到3-乙氧基苯甲醛
  参考文献：
  名称：

  手性N，N-二取代的三氟-3-氨基-2-丙醇是有效的胆固醇酯转移蛋白抑制剂。

  摘要：

  描述了可逆地抑制胆固醇酯转移蛋白（CETP）的一系列新的取代的N-苄基-N-苯基-三氟-3-氨基-2-丙醇。从筛选铅22开始，就抑制CETP介导的[（3）H]胆固醇从高密度胆固醇供体颗粒向低密度胆固醇受体颗粒的转移进行了探索，探讨了各种结构特征。丙醇的游离羟基是高效试剂所必需的，因为酰化或烷基化会降低活性。苯胺环中的3-醚部分也具有高抑制效力，而3-苯氧基苯胺类似物表现出最高的效力。活性通过苄基的亚甲基中的氧化或取代而大大降低，这表明苄基环取向对活性很重要。在苄基中，在3-位的取代优于在2-或4-位。在抑制剂中观察到最高的效力，其中3-苄基取代基具有相对​​于苯环采用平面外取向的潜力。最好的3-苄基取代基是OCF（2）CF（2）H（42，IC（50）缓冲液中0.14 microM，人血清中5.6 microM），环戊基（39），3-异丙氧基（27），SCF （3）（67）和C（CF（3））

  DOI：

  10.1021/jm020038h

文献信息

• Design and synthesis of low molecular weight compounds with complement inhibition activity
  作者：Hoshang E. Master、Shabana I. Khan、Krishna A. Poojari

  DOI：10.1016/j.bmc.2005.04.075

  日期：2005.8

  An attempt was made to synthesize a series of non-cytotoxic low molecular weight compounds of varying substitutions and functionalities having pharmacophore activity like carbonyl compounds, carboxylic acid and bioisosteres like tetrazole and phenyl acrylic acid. The in vitro assay of these analogues for the inhibition of complement activity revealed significant inhibitory activity for varying substituents

  尝试合成一系列具有药效基团活性的，具有不同取代基和功能的，具有不同取代基和官能度的非细胞毒性低分子量化合物，例如羰基化合物，羧酸和生物异构体，例如四唑和苯基丙烯酸。这些类似物在体外对补体活性的抑制作用的测定表明对不同的取代基，特别是对生物等排体，即四唑和苯基丙烯酸衍生物，具有显着的抑制活性。
• [EN] 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS<br/>[FR] DERIVES DE PIPERIDINE 1,4 DISUBSTITUEE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BETAHSD1
  申请人：ASTRAZENECA AB

  公开号：WO2004033427A1

  公开（公告）日：2004-04-22

  The use of a compound of formula (I) in the manufacture of a medicament for use in the inhibition of 11βHSD1 is described.

  使用式(I)的化合物制造用于抑制11βHSD1的药物。
• A reagent based DOS strategy via Evans chiral auxiliary: highly stereoselective Michael reaction towards optically active quinolizidinones, piperidinones and pyrrolidinones
  作者：Subhabrata Sen、Siva R. Kamma、Rambabu Gundla、Uma Adepally、Santosh Kuncha、Sridhar Thirnathi、U. Viplava Prasad

  DOI：10.1039/c2ra22115b

  日期：——

  In the present study, we have demonstrated the diversity oriented synthesis of nitrogen heterocycles viz. chiral piperidinones, quinolizidinones and diaryl pyrrolidinones from Michael adducts generated via a TiCl4-catalyzed highly stereoselective Michael reaction with nitrostyrenes and an Evans chiral auxiliary. We also reported a Cu-4,4’-(isopropyl)-substituted isopropylidene-bridged 2,2’-bis-1,3’-oxazoline catalyst mediated catalytic asymmetric version of this reaction. In silico analysis is utilized to evaluate the diversity of the set of compounds against shape space (PMI), polar surface area (PSA) calculations and relevant drug like properties (viz. HBA, HBD, PSA, mol. wt., log P and log D). Finally, the molecules were screened against microorganisms to assess their antimicrobial properties.

  本研究中，我们展示了以多样性为导向的氮杂环合成，包括手性哌啶酮、喹诺利嗪酮和二芳基吡咯烷酮，这些氮杂环来自通过TiCl4催化的与硝基苯乙烯和对Evans手性辅基的高立体选择性迈克尔反应生成的迈克尔加合物。我们还报道了利用铜-4,4’-（异丙基）-取代异亚丙基桥联的2,2’-双-1,3’-噁唑啉催化剂介导的该反应的催化不对称版本。通过计算机模拟分析评估这一系列化合物的多样性，包括形状空间（PMI）、极性表面积（PSA）计算以及相关的似药性质（例如HBA、HBD、PSA、分子量、log P和log D）。最后，对这些分子进行了针对微生物的筛选，以评估它们的抗菌特性。
• Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry
  作者：Jiangying Cao、Chunhua Ma、Jie Zang、Shuai Gao、Qianwen Gao、Xiujie Kong、Yugang Yan、Xuewu Liang、Qin'ge Ding、Chunlong Zhao、Binghe Wang、Wenfang Xu、Yingjie Zhang

  DOI：10.1016/j.bmc.2018.04.041

  日期：2018.7

  is associated with the tumor angiogenesis and metastasis. In this report, one new series of leucine ureido derivatives containing the triazole moiety was designed, synthesized and evaluated as APN inhibitors. Among them, compound 13v showed the best APN inhibition with an IC50 value of 0.089 ± 0.007 μM, which was two orders of magnitude lower than that of bestatin (IC50 = 9.4 ± 0.5 μM). Compound 13v

  氨基肽酶N在各种恶性细胞上的过表达与肿瘤血管生成和转移有关。在该报告中，设计，合成并评估了一系列新的含有三唑部分的亮氨酸脲基衍生物，并将其评估为APN抑制剂。其中，化合物13v表现出最佳的APN抑制作用，IC50值为0.089±0.007μM，比Bestatin的IC50值低两个数量级（IC50 = 9.4±0.5μM）。化合物13v还显示出剂量依赖性的抗血管生成活性。即使在较低浓度（10μM）下，化合物13v在人脐静脉内皮细胞（HUVEC）毛细血管形成试验和大鼠胸主动脉环试验中也显示出与100μM的Bestatin相似的抗血管生成活性。此外，与Bestatin相比，13v表现出可比性，
• Discovery of Antimetastatic Chiral Ionone Alkaloid Derivatives Targeting HIF‐1α/VEGF/VEGFR2 Pathway
  作者：Jing‐Jing Liu、Xin‐Yao Liu、Jiang‐Ping Nie、Mei‐Qi Jia、Yang Yu、Nan Qin、Hong‐Quan Duan

  DOI：10.1002/cmdc.202100072

  日期：——

  Novel chiral ionone alkaloid derivatives were synthesized and their antimetastatic effects were evaluated in human breast cancer cells using chemotaxis assay. Compared with positive control LY294002, a PI3 K inhibitor, derivatives 10 a, 11 a, 11 c, 11 g, 11 j, 11 k and 11 w exhibited significant inhibitory effects against cancer cell migration. Especially, the IC50 for compound 11 g was as low as 0

  合成了新型手性紫罗兰酮生物碱衍生物，并使用趋化性测定在人乳腺癌细胞中评估了它们的抗转移作用。与阳性对照 LY294002 相比，PI3 K 抑制剂衍生物 10a 、11a、11c、11g、11j、11k和11w对癌细胞迁移具有显着的抑制作用。特别是化合物11 g的IC 50低至0.035±0.004 μM。对化合物11 g的进一步研究表明，它对 MDA-MB-231 细胞的粘附、迁移和侵袭具有抑制作用。11g抗肿瘤转移作用的机制可能是通过抑制 HIF-1α/VEGF/VEGFR2/Akt 通路，从而抑制下游信号分子，包括 Akt1/mTOR/p70S6K 和 Akt2/PKCζ/整合素 β1 通路。综上所述，手性紫罗兰酮生物碱衍生物11 g具有开发成为乳腺癌抗肿瘤转移剂的潜力。

表征谱图